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Abstract 
We have performed a complete screening of the Parkin gene (PRKN2) and looked for p.Gly2019Ser 
(G2019S) and p.Arg1441Gly (R1441G) LRRK2/dardarin gene mutations in twenty seven patients 
with Parkinson’s disease (PD) with an age at onset younger than 50 years (EOPD), living in Gipuz-
koa (Basque Country, Spain). Thirteen of them (48%) were PRKN2 mutation carriers. The c.255- 
256DelA mutation was the most frequent, followed by a deletion involving exons 3 and 4. A dele-
tion involving exons 3 and 12 of the PRKN2 gene and R1441G LRRK2 mutation was found together 
in one PD patient. Four out of fourteen PRKN2 negative patients carried the p.G2019S mutation. 
Both PRKN2 mutation carriers and non-carriers presented frequently with family history (10 PRKN2 
mutation carriers and 8 PRKN2 non-carriers); in fact, five patients without a known gene mutation 
had a first degree relative affected, suggesting another monogenic disease. PRKN2 carriers pre-
sented with a younger age at onset (36.7 vs. 41.7) and more benign disease progression. Indeed, 
those PD patients younger than forty who initially presented with unilateral tremor became 
shortly bilateral. Relatively, symmetric parkinsonism and slow disease progression carried more 
frequently PRKN2 mutations than patients with unilateral akinetic rigid parkinsonism and age at 
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onset later than 40 years. As expected in a recessive disease, PRKN2 patients present more often 
with affected siblings and unaffected patients. The G2019S LRRK2 mutation, less prevalent than 
R1441G in our area, may be also a frequent cause of PD in EOPD (4 patients).  
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1. Introduction 
The probability that Parkinson’s disease (PD) would be a mendelian disorder is higher in patients with age onset 
younger than 50. Three different genes, PRKN2 (OMIM # 602544), PINK1 (OMIM #608309) and PARK7 
(OMIM #602533), have been identified to cause autosomal recessive young onset PD forms [1]-[3]. PRKN2 en-
codes a protein of 465 amino acids named Parkin which functions as an E3-Ubiquitin protein ligase [4] [5]. The 
clinical symptoms of PRKN2 patients are variable, but similar to those found in idiopathic PD. Its phenotype is 
usually characterized by onset before the age of 40 years (may range from 7 to 72 years), good response to 
levodopa therapy, dyskinesias under low doses of levodopa and slow progression. Additional features such as 
dystonia and absence of Lewy bodies (LBs) in the substantia nigra [1] [6] [7] are also frequent. Although the 
absence of LBs in the substantia nigra seems to be frequent in PRKN2 mutation carriers, three PRKN2 cases 
have been reported to show LB pathology [8] [9]. 
LRRK2/dardarin mutations are now a well established cause of typical PD [10]. In our geographical region, 
the Basque Country (Spain), the prevalence of the R1441G mutation is relatively high; in fact, a PD familial pa-
tient of Basque origin has a probability of 46% to carry this mutation [11]. The prevalence of G2019S in this re-
gion is similar to other European countries [11]. 
Here, we analysed the prevalence of PRKN2 and both R1441G and G2019S LRRK2/dardarin mutations in pa-
tients with PD with an age at onset younger than 50 years of a geographical area (Gipuzkoa) of the Basque Country. 
In addition, we inspected the phenotypic differences between PD patients carrying PRKN2 mutations and those 
who were non carriers to establish a range of clinical manifestations that allowed us to make a more accurate 
molecular analysis in our patients with early onset parkinsonism (EOPD)  
2. Subjects and Methods  
2.1. Subjects 
Twenty seven patients were recruited from the Movement Disorders Unit of the Hospital Universitario Donostia, 
Neurology Department. This is a tertiary hospital in the province of Gipuzkoa, Basque Country (Spain), which 
has a population of 700,000 inhabitants. Physical examinations were done by 3 neurologists specialized in move-
ment disorders. PD was diagnosed according to Gelb criteria [12]. A brief clinical questionnaire was completed 
providing information on gender, current age, and age at onset, as well as PD affection status for all first-degree 
relatives of the proband.  
Family history was considered positive if the presence of PD was reported in at least one first degree relative. 
The clinical stages of Parkinsonism were assessed according to the classification of Hoehn and Yahr [13] (H & 
Y) and Unified Parkinson Disease Rating Scale [14] (UPDRS). All participants in this study lived in the Basque 
Country (Spain), mainly in the province of Gipuzkoa, and gave their written consent before participation. All PD 
patients whose onset symptoms began before the age of 50 years were included in this study. Four individuals 
with no family history, absence of movement disorders and an age at onset older than 80 years were also used in 
the gene dosage analysis as neurologically normal individuals. 
Conventionally, the disease progression was categorized as very benign (VB) if after 10 years there the motor 
UPDRS score was less than 2/68, benign (B) if the symptoms progressed to an any incapacity (motor UPDRS 
difference 3 - 6 points), regular(R) if the incapacity was moderate (UPDRS increases 7 - 15 points) and malign 
(M) if the incapacity developed to be severe (more than 15 points in motor UPDRS).  
This work was approved by the ethic committee of Hospital Universitario Donostia. 
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2.2. Molecular Analysis 
DNA was extracted from peripheral blood by a standard phenol chloroform methods and two different approaches 
were performed to analyze the PRKN2 gene. A single-strand conformational polymorphism (SSCP) analysis to 
detect missense mutations and small insertions and deletions [15] was performed after a PCR analysis of the 12 
coding exons of the PRKN2 gene. A direct sequencing analysis to characterize those samples that showed ab-
normalities in the previous SSCP analyses was also performed using an ABI310 Genetic analyzer (Applied 
Biosystems, Foster city, CA). Additionally, a semiquantitative multiplex polymerase chain reaction to detect 
large deletions and duplications was carried out as previously described by Lucking and Brice [16]. This was 
performed for exons 2 through 12 in five different groups: group 1 consisted of exons 2, 3, 9; group 2 consisted 
of exons 6, 8, 10; group 3 consisted of exons 7, 11; group 4 consisted of exons 4, 5; group 5 consisted of only 
exon 12. An external control, a 328 bp sequence of the transthyretin gene (TTR) on chromosome 18, was in-
cluded in all groups and amplified at same time. All PCR products were resolved on an ABI310 Genetic Ana-
lyzer with an internal standard molecular weight (GeneScan 350-ROX; Applied Biosystems, Foster city, CA) 
and analysed using GeneScan v3.6 and Genotyper v3.7 software (Applied Biosystems). A ratio value was ob-
tained comparing all samples to an external standard; the resulting ratios were also compared with ratios ob-
tained from neurologically normal individuals that were run in parallel. All samples were amplified and ran in 
triplicate. The ratio values were interpreted as follows:  
≤0.6 values as an indicative of a heterozygous exon deletion;  
0.8 - 1.2 values as an indicative of a wild type doses;  
1.8 - 2.3 values as an indicative of a homozygous exon duplication or heterozygous exon triplication (all 
primers sequences are available upon requested).  
All subjects were also screened for both LRRK2 c.4321C > G (Ex31, p.Arg1441Gly) and c.6055G > A (Ex41, 
p.Gly2019Ser) mutations. Single nucleotide polymorphism (SNP) genotyping was performed using TaqMan 
chemistry on an ABI7300 following manufacturer’s protocol (Applied Biosystems, Foster City, CA).  
3. Results  
Thirteen out of twenty seven patients with EOPD studied carried PRKN2 mutations (further details are described 
in Table 1). In addition, the R1441G LRRK2 mutation was identified in a PD patient carrying as well a het- 
erozygous deletion involving exons 3 and 12 of the PRKN2 gene. The G2019S mutation was present in four out 
of fourteen patients who did not show any pathogenic PRKN2 variant (further details are described in Table 2). 
 
Table 1. Patients with PRKN2 mutations.                                                                           
Patients Sex Family history 
Age at 
onset 
(years) 
Symptoms 
Duration 
symptoms 
(years) 
L-dopa 
response Progression Dysk Fluct H & Y 
PRKN2 
mutations 
LRRK2  
mutations 
1 M Mt 44 T-LL 9 G + - - 1 Delx3-x12 p.Arg1441Gly 
2 M Un 49 T-Un 7 G + - - 2 p.Arg402Cys/Multiple  exon rearrangements - 
3 M B 43 A, G 13 G ++ - + 3 Delx3-x4/Delx3-x4 - 
4 F B 39 T-Bi 12 G + - - 2 Delx3-x4/Delx3-x4 - 
5 F B 26 A 35 G +++ + + 4 c.202_203delAG/Delx4 - 
6 F B 41 T-Uni 18 G - + + 0 c.202_203delAG/Delx4 - 
7 M B 23 T-Uni 27 G ++ + + 3 c.255-256delA/c.255-256delA - 
8 F B 27 T-Bi 28 G + + + 2.5 c.255-256delA/c.255-256delA - 
9 M - 28 T-UL 7 G - - - 1 c.255-256delA/Delx4-x5 - 
10 F B 38 T-Bi 29 G - + + 1 c.255-256delA/c.255-256delA - 
11 M B 43 T-Bi 29 G - + + 2.5 c.255-256delA/c.255-256delA - 
12 F - 34 T-Bi 27 NT - - - 2 c.255-256delA/c.255-256delA - 
13 M - 43 T-UL 27 G - + - 2 Delx5/Delx5 - 
Sex: M: male, F: female; Family history: Mt: mother, Un: uncle, B: brother; Symptoms: T: tremor, LL: low limb, Uni: unilateral, A: akinesia, Bi: bilateral, UL: 
upper limb, G: gait disturbance; L-dopa response: G: good, R: regular, P: poor, NT: not tolerated; Progression: VB: very benign (−), B: benign (+), R: regular 
(++), M: malignant (+++); DysK: dyskinesias; Fluct: fluctuations. 
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Table 2. Patients without PRKN2 mutations.                                                                         
Patients Sex Family history 
Age at 
onset 
(years) 
Symptoms 
Duration 
symptoms 
(years) 
L-dopa 
response Progression Dysk Fluct H & Y LRRK2 mutations 
1 M - 48 R 3 G ++ - - 2.5 p.Gly2019Ser 
2 F - 39 T-UL 19 G + + + 3 - 
3 M Mt-GF 47 T-Uni 20 G ++ + + 3 p.Gly2019Ser 
4 M Mt 24 A 3 Und Und - - 1.5 - 
5 M - 46 T-UL 6 Und Und - - 1 - 
6 M - 38 T-UL 26 G ++ + + 4 - 
7 M Mt-Un 49 T-UL 10 G + + - 2 - 
8 F - 48 A,R 17 R +++ + + 4 - 
9 M F-GF 48 T-bi 20 R + - - 2 - 
10 F F 43 T-Uni 18 R ++ + + 4 - 
11 M F-B 49 A 3 Und Und - - 1.5 p.Gly2019Ser 
12 F Mt 48 A 11 P + - - 2 - 
13 M F 37 Dy 15 P ++ + + 4 p.Gly2019Ser 
14 M - 21 A 4 Und Und - - 1.5 - 
Sex: M: man, F: woman; Family history: Mt: mother, Un: uncle, B: brother, F: Father, GF: grandfather; Symptoms: T: tremor, LL: low limb, Uni: Unilateral, A: 
akynesia, Bi: bilaterall, UL: upper limb; G: gait disturbance; R: rigidity, Dy: dystonia; L-dopa response: G: good, R: regular, P: poor, NT: not tolerated, Und: 
undeterminated; Progression: VB: very beningn (−), B: benign (+), R: regular (++), M: malign (+++), Und: undeterminated; DysK: dyskinesias; Fluct: fluctua-
tions. 
3.1. PRKN2 Mutations 
Homozygous c.255-256delA mutations were found in four individuals from two different families (patients 7, 8, 
10 and 11), and in an apparently sporadic case (patient 12). This was the most frequent genetic abnormality 
identified. It was also present along with a heterozygous deletion implying exons 4 and 5 in another apparently 
sporadic case (patient 9). Two affected individuals from the same family (patients 5 and 6) were found to carry 
three heterozygous PRKN2 mutations: an exon 4 deletion (Delx4), a small deletion involving only two bases 
(c.202_203delAG) and the missense p.Gly94Ser variant. This indicates that one of the parents was also a com-
pound heterozygous PRKN2 mutation carrier, however neither the father nor mother was known to be affected 
when they died, both 80 years old. A homozygous exon deletion involving exons 3 and 4 was found in two 
manifesting members of a PD family (patients 3 and 4). A p.Arg402Cys missense variant along with a large de-
letion involving exons 3, 4, 7, 8, 9, 10 and 12 were present in an possible recessive inheritance pattern (patient 
2), suggesting that this case may belong to a PD family in which there may be more PRKN2 mutation carriers. 
Analysis of this large deletion in additional members was not possible to carry out, being unable to determine if 
these deletions occur in cis or in trans to one another. The last mutation reported here is a exon 5 homozygous 
deletion that was identified in a sporadic PD patient (patient 13). 
In addition we found 4 different exon deletions involving exons, 3, 4 and 5: Delx4, Delx3-x4, Delx4-x5 and 
Delx5.  
3.2. Clinical Phenotype 
Patients with PRKN2 mutations (see Table 1) 
Six women and seven men carried PRKN2 mutations and their age at onset ranged from 23 to 49 years (mean 
age at onset: 36.76 years). Ten had a family history of PD. The patient with digenic mutations (PRKN2/LRRK2) 
had a family history compatible with an autosomal dominant pattern of inheritance, having the mother suffered 
from PD. One patient had an uncle affected with PD and the remaining eight had affected siblings who carried 
J. F. Martí Massó et al. 
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the same mutation following a recessive inheritance pattern.  
Tremor was the onset symptom in eleven patients, of which six presented with bilateral hand tremor. The 
tremor was unilateral in the remaining seven but, in less than 2 years, it progressed to be bilateral. Clumsiness 
and gait disturbances were the onset symptoms in just two patients.  
Duration of disease was at least 7 years at the time of examination (from 7 to 35 years), allowing us to accu-
rately determine their phenotypic characteristics. The response to levodopa therapy was good in all patients, ex-
cept for one that did not tolerate it well when she first tried. During the 17 years of the disease progression, she 
never was under levodopa therapy.  
The disease progression was extremely benign in some of them who after many years of evolution could have 
a regular life. Furthermore, it is worth noting that two siblings carrying the same PRKN2 mutations (202- 
203ΔAG/Delx4) presented with a completely different disease progression. Patient with severe evolution con-
sumed higher doses of levodopa than those prescribed, while his sister takes always small levodopa doses. 
Patients without PRKN2 mutations (see Table 2) 
Among the ten men and four women who were PRKN2 mutation non-carriers, four carried the G2019S muta-
tion in the LRRK2 gene. The onset of symptoms ranged from 21 to 49 years with a mean age at onset of 41.7 
years, although in eight patients symptoms began after age 45. Three out of four patients carrying G2019S mu-
tation were diagnosed in their fifties. Eight patients described an autosomal dominant pattern of inheritance, 5 
patients were recessive and only one who carried the G2019S mutation was sporadic.  
Seven patients presented with tremor, being unilateral in six of them and bilateral only in one. An akinetic 
rigid syndrome was present as the initial symptom in one patient.  
The progression of disease has been slow in four patients, regular in five and very bad in one who showed 
many complications from the disease onset, accumulating significant disability. Overall, the disease progression 
was significantly more benign in PRKN2 mutation carriers than non-carriers (X. p = 0.04).  
4. Discussion 
In the Province of Gipuzkoa (The Basque Country, Spain), where the prevalence and incidence of PD is similar 
to other European countries [17], the prevalence of the p.Arg1441Gly/LRRK2 mutation is relatively high [11]. In 
this study we have also found a high prevalence of PRKN2 mutations. Therefore, one may speculate that other 
mutations may be more prevalent in different geographic areas. In this work we present prevalence of PRKN2 
and LRRK2 mutations in a cohort of EOPD in a region with a population which is possibly unique and different 
from others. 
An extensive review of PRKN2 mutations identified the most common mutations as deletions of exon 4 (7.38%), 
deletions of exon 3 (6.06%), deletions of exons 3 and 4 (6.06%), a point mutation in exon 7 (c.924C > T, 
10.02%) and a single base pair deletion in exon 2 (c.255-256delA, 4.48%) [18]. Four of these five common mu-
tations occurred in our sample, confirming that the hot spots for small mutations may be concentrated in exon 2 
and for break points in introns 2 through 4. In our sample, the most common mutation found was c.255-256delA. 
The frequency of homozygous carriers for c.255-256delA has been estimated at 1/40.000 in the Spanish popula-
tion [19], supporting the hypothesis of a possible Spanish founder for this mutation. 
The presence of family history is relatively high in our sample analyzed (66.67%); indeed, 44.45% showed an 
autosomal recessive pattern of inheritance with affected siblings carrying the same genetic defect. All autosomal 
recessive patients carried PRKN2 mutations, compiling a total of 29.6% of the cases here described. This pro-
portion is similar to those reported in other studies [20]-[22]. In addition, the patient who carries heterozygous 
PRKN2 deletions involving exons 3 and 12, and the R1441G mutation of LRRK2, had a family history compati-
ble with autosomal dominant inheritance (two unaffected brothers and an affected parent). An additional PRKN2 
mutation carrier had also an affected uncle. 
With respect to the cases without PRKN2 mutations, 6 familial individuals presented with strong genetic back-
ground compatible with an autosomal dominant pattern of inheritance.  
The phenotypic characteristics found in the cases reporting PRKN2 mutations resemble to those described in 
most of the genetic studies to date reported [20]-[23]. The PRKN2-associated phenotype is well defined and 
broadly similar; the main clinical manifestations are the young age at onset, and the benign disease progression. 
The majority of the cases began with tremor which can be unilateral and/or progress to be bilateral and occa-
sionally accompanied with postural tremor. Additionally, some of the cases presenting with akinesia or gait dis-
turbances have a more severe disease progression than those initially presenting with tremor, being similar to 
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that found in PRKN2 mutation non-carriers who showed dystonia or akinesia as initial symptom. None of our 
patients have dystonia, diurnal fluctuations, exercise induced dystonia, psychosis or peripheral neuropathy de-
scribed elsewhere [23]. 
In this study the evolution in patients with PRKN2 mutations is more benign. In 5 patients, we considered the 
evolution very benign, presenting only mild parkinsonian signs in exploration under small doses of antiparkin-
sonian medication, many years after the onset of symptoms. Phenotype-genotype dissociations were observed in 
2 sisters presenting with very different clinical evolution, suggesting that other genetic or environmental factors 
and behaviours may possibly justify these differences. The PD with double mutation (PRKN2/LRRK2) had a 
similar age at onset (44 years) to the other PRKN2 mutation carriers; suggesting that to carry pathological muta-
tions in both genes does not have an effect on the disease features.  
An important issue is to reflect on the value of the molecular study of the PRKN2 gene in EOPD. In our series, 
although the age of onset of symptoms did not differ statistically between both groups (36.7 in PRKN2 carriers 
versus 41.7 in the PRKN2 non carriers), probably because of the sample size, PD patients that present with the 
disease after age 45 are less likely to have a PRKN2 mutation. Autosomal recessive patients with an age at onset 
lower than 45 years and showing a typical idiopathic PD are highly susceptible to carry PRKN2 mutations.  
Given the lack of screening for PARK7 and PINK-1 mutations and PRKN2 promoter variations in our nega-
tive PRKN2 mutation cases, we cannot exclude that in these cases PD may be caused by alterations in one of 
these genes. Other mutations in LRRK2 are uncommon and did not be studied. In our study we observed that 
PRKN2 mutations are more frequent in early onset familial cases than in early-onset sporadic cases (frequency 
of 0.26). 
We recognize in this work the limitation that supouse of having looked for only the p.Arg1441Gly and 
p.Gly2019Ser mutations in the LRRK2 gene, and mutations in PKRN2 gene. It is true that the study would have 
been more consistent if the number of patients studied had been greater, and if we had included other pathogenic 
mutations in the LRRK2 gene and mutations in other genes involved in recessive forms of PD as PINK1 and 
PARK7. 
In our opinion, with the limitations of this small sample, in our region knowing whether someone may or may 
not carry PRKN2 mutations have some advantages, such as warning about the possibility to be a carrier and help-
ing in an accurate genetic counseling, and somehow in the prognosis of the disease; indeed, the therapeutic strategy 
might be different.  
5. Conclusions 
Forty eight percent of the 27 PD patients with age of onset before 50 were PRKN2 mutation carriers. The c.255- 
256DelA mutation was the most frequent, followed by a deletion involving exons 3 and 4. A deletion involving 
3 and 12 of the PRKN2 gene and R1441G LRRK2 mutation was found together in one PD patient.  
Four out of fourteen PRKN2 negative patients carried the pG2019S mutation of the LRRK2 gene.  
Both PRKN2 mutation carriers and non-carriers presented frequently with family history (10 PRKN2 mutation 
carriers and 8 PRKN2 non-carriers); in fact, five patients without a known gene mutation had a first degree rela-
tive affected, suggesting another monogenic disease.  
PRKN2 carriers presented with a younger age at onset (36.7 vs. 41.7) and more benign disease progression. 
Indeed, those PD patients younger than forty who initially presented with unilateral tremor became shortly bi-
lateral. Relatively, symmetric parkinsonism and slow disease progression carried more frequently PRKN2 muta-
tions than patients with unilateral akinetic rigid parkinsonism and age at onset later than 40 years. As expected 
in a recessive disease, PRKN2 patients present more often with affected siblings and unaffected parents.  
The G2019S LRRK2 mutation, less prevalent than R1441G in our area, may be also a frequent cause of PD in 
EOPD (4 patients).  
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